Emerging research suggest this peptide, a dual activator targeting both the gut-brain axis and GIP , appears to represent a promising step forward for obesity management . Early patient tests have indicated considerable losses in abdominal fat , potentially surpassing current weight-loss therapies . Despite this, further assessment is required to f